- Conditions
- Plantar Fasciitis
- Interventions
- Injection of 1.0 cc of 0.9% Saline, Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension, Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension, Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension
- Procedure
- Lead sponsor
- MiMedx Group, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Roanoke, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1921–1944
of 1,988
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pain, Postoperative, Premature Infant, Opioid Use
- Interventions
- Acetaminophen, Saline
- Drug
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- Up to 1 Month
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Stenosis, Herniated Nucleus Pulposus, Degenerative Disc Disease, Spondylosis, Myelopathy, Radiculopathy, Myeloradiculopathy
- Interventions
- Methylprednisolone, Saline
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Iron, Abnormal Blood Level
- Interventions
- Transfusion of red blood cells, Infusion of albumin/saline
- Biological
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Chronic Exertional Compartment Syndrome
- Interventions
- Supervised Gait Retraining, Home Based Gait Retraining, Saline Injection, Botulinum Toxin Injection
- Behavioral · Drug
- Lead sponsor
- Walter Reed National Military Medical Center
- Federal
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Bethesda, Maryland • Fort Bragg, North Carolina • Killeen, Texas + 1 more
- Conditions
- Seizures
- Interventions
- Bumetanide, Normal Saline as Placebo
- Drug
- Lead sponsor
- Soul, Janet , M.D.
- Individual
- Eligibility
- Up to 44 Weeks
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts
- Conditions
- Alcoholic Hepatitis
- Interventions
- DUR-928 (Moderate AH), DUR-928 (Severe AH)
- Drug
- Lead sponsor
- Craig James McClain
- Other
- Eligibility
- 21 Years to 67 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Influenza, Pandemic
- Interventions
- BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette - IN, BW-1014: 100 µg rH5 in 20% NE - pipette - IN, rH5 (100 µg) control - pipette - IN, Saline (Placebo) - pipette - IN, H5N1 IIV - IM
- Biological
- Lead sponsor
- BlueWillow Biologics
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Limited Stage Small Cell Lung Cancer
- Interventions
- Trilaciclib, Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Pharmacosmos A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Dry Eye, Dry Eye Disease (DED), Dry Eye Disease With Severe Keratitis
- Interventions
- TTAX03, Saline (NaCl 0,9 %) (placebo)
- Biological
- Lead sponsor
- BioTissue Holdings, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 9
- States / cities
- Berkeley, California • Deerfield Beach, Florida • Chaska, Minnesota + 6 more
- Conditions
- Graft vs Host Disease
- Interventions
- Begelomab, Conventional Second-line Treatment
- Biological
- Lead sponsor
- Adienne SA
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 10
- States / cities
- Duarte, California • Westwood, Kansas • Boston, Massachusetts + 7 more
- Conditions
- Anaemia
- Interventions
- Daprodustat tablets, Matching placebo tablets, Epoetin alfa vials, Saline vials or bags
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 23
- States / cities
- Mesa, Arizona • Fresno, California • Los Angeles, California + 19 more
- Conditions
- Corneal Neovascularization, Corneal Graft Failure
- Interventions
- Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel
- Drug
- Lead sponsor
- Reza Dana, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 3
- States / cities
- Miami, Florida • Boston, Massachusetts • New York, New York
- Conditions
- Hallux Valgus
- Interventions
- TLC590, Naropin®, Normal Saline, Bupivacaine
- Drug
- Lead sponsor
- Taiwan Liposome Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more
- Conditions
- Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
- Interventions
- Imvotamab, Placebo
- Drug
- Lead sponsor
- IGM Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Flagstaff, Arizona • Glendale, Arizona • San Diego, California + 7 more
- Conditions
- Pancreatitis, Pancreatitis, Acute, Corticosteroid, Hydrocortisone
- Interventions
- Hydrocortisone, Placebo
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Bupivacaine, patient-reported pain scores, saline
- Drug · Behavioral · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Rupture of Anterior Cruciate Ligament
- Interventions
- Bupivacaine, Preservative free normal saline
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute Hepatic Porphyria, Acute Intermittent Porphyria, Porphyria, Acute Intermittent, Acute Porphyria, Hereditary Coproporphyria (HCP), Variegate Porphyria (VP), ALA Dehydratase Deficient Porphyria (ADP)
- Interventions
- Givosiran, Placebo
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • San Francisco, California • Boston, Massachusetts + 7 more
- Conditions
- Parenteral Nutrition
- Interventions
- Sodium Glycerophosphate Injection, Sodium Phosphates Injection
- Drug
- Lead sponsor
- Baxter Healthcare Corporation
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Osteoarthritis, Knee
- Interventions
- EUFLEXXA™, placebo
- Device
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 588 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Sialorrhea
- Interventions
- Incobotulinum Toxin A, Placebo
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Atopic Asthma, Healthy
- Interventions
- House Dust Mite, Diluent
- Biological
- Lead sponsor
- John Sundy
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Asthma
- Interventions
- INTRAVENOUS GSK679586, INTRAVENOUS PLACEBO, FLUTICASONE PROPIONATE
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 6
- States / cities
- Medford, Oregon • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more